IP Library › Granted Patent US 12,264,196
Granted Patent B2
US 12,264,196 · App. 16/590,938 · Granted Apr 1, 2025

Fc-receptor binding modified asymmetric antibodies and methods of use

Inventors: Joerg Thomas Regula (Munich, DE); Wolfgang Schaefer (Mannheim, DE); Tilman Schlothauer (Penzberg, DE)
Assignee: Hoffmann-La Roche Inc.
C07K16/22C07K16/00C07K16/2863C07K16/468A61K2039/505A61K2039/54C07K2317/31C07K2317/33C07K2317/35C07K2317/41C07K2317/52C07K2317/56C07K2317/565C07K2317/71C07K2317/92C07K2317/94
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,264,196
App. No.
16/590,938
Granted
Apr 1, 2025
Kind
B2
Abstract

The present invention relates to antibodies and Fc-region fusion polypeptides which are asymmetrically modified with respect to their Fc-receptor, especially their FcRn, and methods of using the same.

Claims (34)

1. An IgG1 Fc-region, comprising a first Fc-region polypeptide and a second Fc-region polypeptide, wherein:

the first and the second Fc-region polypeptide are human IgG1 Fc-region polypeptide of SEQ ID NO: 60 and have the following mutations (numbering according to Kabat EU index numbering system):

1253A in the first variant Fc-region polypeptide, and H310A and H435A in the second variant Fc-region polypeptide, or

I253A and H310A in the first variant Fc-region polypeptide, and H435A in the second variant Fc-region polypeptide, or

1253A and H435A in the first variant Fc-region polypeptide, and H310A in the second variant Fc-region polypeptide; and

wherein:

the IgG1 Fc-region has an affinity to a human Fc-receptor that is decreased in comparison to that of an IgG1 Fc-region that does not have said mutations,

wherein

i) the first IgG1 Fc-region polypeptide is a human IgG1 Fc-region polypeptide with the mutations L234A, L235A and the second IgG1 Fc-region polypeptide is a human IgG1 Fc-region polypeptide with the mutations L234A, L235A, or

iii) the first IgG1 Fc-region polypeptide is a human IgG1 Fc-region polypeptide with the mutations L234A, 1235A, P329G and the second IgG1 Fc-region polypeptide is a human IgG1 Fc-region polypeptide with the mutations L234A, L235A, P329G, or

iv) the first IgG1 Fc-region polypeptide is a human IgG1 Fc-region polypeptide with the mutations L234A, L235A, S354C, T366W and the second IgG1 Fc-region polypeptide is a human IgG1 Fc-region polypeptide with the mutations L234A, L235A, Y349C, T366S, L368A, Y407V, or

v) the first IgG1 Fc-region polypentide is a human IgG1 Fc-region polypeptide with the mutations L234A, L235A, P329G, S354C, T366W and the second IgG1 Fc-region polypeptide is a human IgG1 Fc-region polypeptide with the mutations L234A, L235A, P329G, Y349C, T366S, L368A, Y407V, or

or

vi) the first IgG1 Fc-region polypeptide is a human IgG1 Fc-region polypeptide with the mutation K392D and the second IgG1 Fc-region polypeptide is a human IgG1 Fc-region polypeptide with the mutations D399K, D356K, and/or E357K, and

wherein the IgG1 Fc-region has a reduced binding to Staphylococcus protein A than an IgG1 Fc-region comprising the first IgG1 Fc-region polypeptide of a) and the second IgG1 Fc-region polypeptide of a).

2. The IgG1 Fc-region according to claim 1 , wherein the affinity to the human neonatal Fc-receptor is increased or reduced by 10% or more determined by surface plasmon resonance (SPR).

3. The IgG1 Fc-region according to claim 1 , characterized in comprising the mutations M252Y/S254T/T256E in the Fc-region (numbering according to Kabat EU index numbering system), whereby i) all mutations are in the first or the second Fc-region polypeptide, or ii) one or two mutations are in the first Fc-region polypeptide and one or two mutations are in the second Fc-region polypeptide so that all of the mutations M252Y/S254T/T256E are comprised in the IgG1 Fc-region.

4. An antibody comprising the IgG1 Fc-region according to claim 1 .

5. The antibody according to claim 4 , wherein the antibody is a monoclonal antibody.

6. The antibody according to claim 4 , wherein the antibody is a human, humanized, or chimeric antibody.

7. The antibody according to claim 4 , wherein the antibody is a bispecific antibody.

8. The antibody according to claim 4 , wherein the antibody is a bivalent antibody.

9. The antibody according to claim 4 , wherein the antibody is a bispecific, bivalent antibody with abolished FcRn binding comprising a first antigen-binding site that specifically binds to human VEGF and a second antigen-binding site that specifically binds to human ANG-2.

10. A bispecific, bivalent antibody with abolished FcRn binding comprising a first antigen-binding site that specifically binds to human VEGF and a second antigen-binding site that specifically binds to human ANG-2,

wherein

α) the first antigen-binding site specifically binding to VEGF comprises in the heavy chain variable domain a CDR3H region of SEQ ID NO: 14, a CDR2H region of SEQ ID NO: 15, and a CDR1H region of SEQ ID NO: 16, and in the light chain variable domain a CDR3L region of SEQ ID NO: 17, a CDR2L region of SEQ ID NO: 18, and a CDR1L region of SEQ ID NO: 19, and

β) the second antigen-binding site specifically binding to ANG-2 comprises in the heavy chain variable domain a CDR3H region of SEQ ID NO: 22, a CDR2H region of, SEQ ID NO: 23, and a CDR1H region of SEQ ID NO: 24, and in the light chain variable domain a CDR3L region of SEQ ID NO: 25, a CDR2L region of SEQ ID NO: 26, and a CDR1L region of SEQ ID NO: 27, and γ) the bispecific antibody comprises an IgG1 Fc-region according to claim 1 .

11. The bispecific antibody according to claim 10 , wherein

α) the first antigen-binding site specifically binding to VEGF comprises as heavy chain variable domain VH an amino acid sequence of SEQ ID NO: 20 and as light chain variable domain VL an amino acid sequence of SEQ ID NO: 21, and

β) the second antigen-binding site specifically binding to ANG-2 comprises as heavy chain variable domain VH an amino acid sequence of SEQ ID NO: 28 and as light chain variable domain VL an amino acid sequence of SEQ ID NO: 29, and

γ) the bispecific antibody comprises an IgG1 Fc-region according to claim 1 .

12. An Fc-region fusion polypeptide comprising the IgG1 Fc-region according to claim 1 .

13. A pharmaceutical formulation comprising the antibody according to claim 4 .

14. A pharmaceutical formulation comprising the Fe region fusion polypeptide according to claim 12 .

Priority Claims (2)
EP 13165725 · Apr 29, 2013 · regional
EP 14151314 · Jan 15, 2014 · regional
Continuity (3)
Continuation 14927022 · Oct 29, 2015
Continuation PCTEP2014058416 · Apr 25, 2014
Related Publication 20200095310A1 · Mar 26, 2020
References Cited (155)
US 6277375B1 · Ward · 2001 [cited by examiner]
US 6737056B1 · Presta · 2004 [cited by applicant]
US 7695936B2 · Carter · 2010 [cited by examiner]
US 7923538B2 · Shitara et al. · 2011 [cited by applicant]
US 8227577B2 · Klein et al. · 2012 [cited by applicant]
US 9217880B2 · Pugh et al. · 2015 [cited by applicant]
US 9695233B2 · Duerr · 2017 [cited by examiner]
US 10195262B2 · Wacker et al. · 2019 [cited by applicant]
US 10316092B2 · Yao et al. · 2019 [cited by applicant]
US 11091541B2 · Hartmann · 2021 [cited by examiner]
US 20050249723A1 · Lazar · 2005 [cited by applicant]
US 20060067930A1 · Adams et al. · 2006 [cited by applicant]
US 20070219133A1 · Lazar et al. · 2007 [cited by applicant]
US 20090136936A1 · Georgiou et al. · 2009 [cited by applicant]
US 20090162360A1 · Klein et al. · 2009 [cited by applicant]
US 20100093979A1 · Lazar · 2010 [cited by applicant]
US 20100111967A1 · Baehner · 2010 [cited by examiner]
US 20100184959A1 · Guler-Gane et al. · 2010 [cited by applicant]
US 20100203046A1 · van Vlijmen et al. · 2010 [cited by applicant]
US 20110288276A1 · Oganesyan et al. · 2011 [cited by applicant]
US 20120134984A1 · Lubman et al. · 2012 [cited by applicant]
US 20120251531A1 · Baehner et al. · 2012 [cited by applicant]
US 20120282280A1 · Bramlage et al. · 2012 [cited by applicant]
US 20130039913A1 · Labrijn et al. · 2013 [cited by applicant]
US 20130131319A1 · Igawa et al. · 2013 [cited by applicant]
US 20130247234A1 · McWhirter et al. · 2013 [cited by applicant]
US 20140017244A1 · Duerr · 2014 [cited by examiner]
US 20150175707A1 · De Jong et al. · 2015 [cited by applicant]
US 20160231320A1 · Young et al. · 2016 [cited by applicant]
BR 102016022721A2 · 2018 [cited by applicant]
CA 3159061A1 · 2013 [cited by applicant]
EP 1601697B1 · 2007 [cited by applicant]
WO 9734631A1 · 1997 [cited by applicant]
WO 9845331A2 · 1998 [cited by applicant]
WO 2004035752A2 · 2004 [cited by applicant]
WO 2005005635A2 · 2005 [cited by applicant]
WO 2005016967A2 · 2005 [cited by applicant]
WO 2005035752A2 · 2005 [cited by applicant]
WO 2005058967A2 · 2005 [cited by applicant]
WO 2005061541A2 · 2005 [cited by applicant]
WO 2005077981A2 · 2005 [cited by applicant]
WO 2006039137A2 · 2006 [cited by applicant]
WO 2006053301A2 · 2006 [cited by applicant]
WO 2006072620A1 · 2006 [cited by applicant]
WO 2007110339A1 · 2007 [cited by applicant]
WO 2009045389A2 · 2009 [cited by applicant]
WO 2009058492A2 · 2009 [cited by applicant]
WO 2010066868A2 · 2010 [cited by applicant]
WO 2010099137A2 · 2010 [cited by applicant]
WO WO2011008517A2 · 2011 [cited by applicant]
WO 2011117330A1 · 2011 [cited by applicant]
WO 2012058768A1 · 2012 [cited by applicant]
WO 2012069557A1 · 2012 [cited by applicant]
WO 2012083370A1 · 2012 [cited by applicant]
WO 2012093125A1 · 2012 [cited by applicant]
WO 2013056233A1 · 2013 [cited by applicant]
WO 2013063702A1 · 2013 [cited by applicant]
WO WO2013060867A2 · 2013 [cited by examiner]
WO 2013166594A1 · 2013 [cited by applicant]
WO 2014036385A1 · 2014 [cited by applicant]
WO 2014177459A2 · 2014 [cited by applicant]
WO WO2014177460A1 · 2014 [cited by examiner]
WO 2015057668A1 · 2015 [cited by applicant]
Chamow et al. The Journal of Immunology. 1994; 153:4268-4280. (Year: 1994). [cited by examiner]
Chamow et al. The Journal of Immunology. 1994; 153:4268-4280. (Year: 1994) (Year: 1994). [cited by examiner]
Adams et al., “Structure and function of the type 1 insulin-like growth factor receptor.” Cell Mol Life Sci 57(7):1050-93. (Jul. 2000). [cited by applicant]
Avdeeva Z.I., et al., “Preparations of next generation monoclonal antibodies (issues and prospects),” BIOpreparations. Prevention, Diagnosis, Treatment. 2015;(1):21-35. (In Russ.) English abstract included. [cited by applicant]
Chiu et al., “Associations between Genetic Polymorphisms of Insulin-like Growth Factor Axis Genes and Risk for Age-Related Macular Degeneration,” Invest Ophthalmol Vis Sci., 52(12): 9099-9107, Nov. 24, 2011. [cited by applicant]
Diamond B., Scharff M.D. “Somatic mutation of the T15 heavy chain gives rise to an antibody with autoantibody specificity”, Proc. Natl. Acad. Sci. USA, 1984, vol. 81, abstract. [cited by applicant]
Folkman and Shing, “Angiogenesis” J Biol Chem 267(16):10931-10934 (Jun. 5, 1992). [cited by applicant]
Garner, A. Pathobiology of Ocular Disease. A Dynamic Approach “Vascular Diseases” Garner, A., Klintworth GK Eds., 2nd edition, NY:Marcel Dekker,:1625-1710 ( 1994). [cited by applicant]
Ghetie and Ward, “FcRn: the MHC class I-related receptor that is more than an IgG transporter” Immunol Today 18 (12):592-598 (Dec. 1997). [cited by applicant]
Hezareh et al., “Effector Function Activities of a Panel of Mutants of a Broadly Neutralizing Antibody Against Human Immunodeficiency Virus Type 1,” J Virol, Dec. 2001;75(24):12161-8. [cited by applicant]
Jaeger L. “Kliničeskaâ immunologiâ i allergologiǎ”, 2nd edition, translation from German, M.: Medicina, 1990, in 3 volumes, vol. 2, pp. 484-485. [cited by applicant]
JArilin A.A., “Osnovy immunologii” [“Basics of Immunology”], M.: Medicina, 1999, pp. 170-171, figure 41. [cited by applicant]
Kenanova et al., “Tailoring the Pharmacokinetics and Positron Emission Tomography Imaging Properties of Anti-Carcinoembryonic Antigen Single-Chain Fv-Fc Antibody Fragments,” Cancer Res 65(2): 622-630 (Year: 2005). [cited by applicant]
Klagsbrun and D'Amore, “Regulators of angiogenesis” Ann Rev Physiol 53:217-239, ( 1991). [cited by applicant]
LeRoith et al., “Molecular and cellular aspects of the insulin-like growth factor I receptor” Endocr Rev 16(2):143-63 (Apr. 1995). [cited by applicant]
Ohno et al., “Antigen-binding specificities of antibodies are primarily Determined by seven residues of VH,” Proc Natl Acad Sci USA_82_1985, pp. 2945-2949. [cited by applicant]
Roitt, A et al, Immunology, Moscow, “Mir”, 2000, p. 98_EN Translation. [cited by applicant]
Roitt, A. et al., Immunology, Moscow, “Mir” (2000) pp. 110-111 (copy and English translation attached). [cited by applicant]
Chinese Office Action, mailed on Mar. 22, 2019, in the related Chinese Patent Application No. 201580003626.0. [cited by applicant]
Chinese Office Action, mailed on Jun. 4, 2020, in the related Chinese Patent Application No. 201480023252.4. [cited by applicant]
Israeli Office Action, mailed on Sep. 17, 2020, in the related Israeli Patent Application No. 274398. [cited by applicant]
Japanese Office Action, mailed on Jul. 5, 2018, in the related Japanese Patent Application No. 2016-511014. [cited by applicant]
Japanese Office Action, mailed on Nov. 20, 2018, in the related Japanese Patent Application No. 2016-546942. [cited by applicant]
Japanese Office Action, mailed on Dec. 4, 2018, in the related Japanese Patent Application No. 2016-546941. [cited by applicant]
Japanese Office Action, mailed on Apr. 28, 2020, in the related Japanese Patent Application No. 2016-546941. [cited by applicant]
Japanese Office Action, mailed on Jun. 2, 2020, in the related Japanese Patent Application No. 2019-097631. [cited by applicant]
Korean Office Action, mailed on Aug. 31, 2020 , in the related Korean Appl. No. 2015-7031019. [cited by applicant]
Korean Office Action, mailed on Sep. 21, 2020, in the related Korean Patent Application No. 10-2015-7033963. [cited by applicant]
New Zealand Office Action, mailed on Oct. 30, 2020, in the related New Zealand Appl. No. 751585. [cited by applicant]
Russian Office Action, mailed on Jun. 22, 2018, in the related Russian Patent Application No. 2016133346. [cited by applicant]
Russian Office Action, mailed on Aug. 8, 2018, in the related Russian Patent Application No. 2016133347. [cited by applicant]
Russian Office Action, mailed on Mar. 13, 2019, in the related Russian Patent Application No. 2016133347. [cited by applicant]
Russian Office Action, mailed on Oct. 31, 2018, in the related Russian Patent Application No. 2016133345. [cited by applicant]
Russian Office Action, mailed on Sept. 6, 2018, in the related Russian Patent Application No. 2015145719. [cited by applicant]
Russian Office Action, mailed on Oct. 18, 2018, in the related Russian Patent Application No. 2015145719. [cited by applicant]
Russian Office Action, mailed on Apr. 27, 2020, in the related Russian Patent Application No. 2016133345. [cited by applicant]
Russian Office Action, mailed on May 27, 2020, in the related Russian Patent Application No. 2016 133 346. [cited by applicant]
Taiwanese Office Action, mailed on May 26, 2020, in the related Taiwanese Appl. No. 108105062. (Translation). [cited by applicant]
The European Search Report and Opinion, mailed on Sep. 24, 2013,in the related European Appl. No 14721806.9. [cited by applicant]
The European Search Report and Opinion, mailed on Mar. 27, 2018, in the related European Appl. No 17205688.9. [cited by applicant]
The European Search Report and Opinion, mailed on Feb. 24, 2020,in the related European Appl. No 19183116.3. [cited by applicant]
US Office Action, mailed on Sep. 5, 2018, in the related U.S. Appl. No. 14/785,900. [cited by applicant]
US Office Actions, mailed on Aug. 10, 2020 and Nov. 17, 2020, in the related U.S. Appl. No. 15/947,377. [cited by applicant]
US Office Action, mailed on Aug. 24, 2020, in the related U.S. Appl. No. 15/947,424. [cited by applicant]
US Office Actions, mailed on Aug. 28, 2018, Mar. 14, 2019, Jan. 2, 2020, Aug. 31, 2020 and Dec. 14, 2020, in the related U.S. Appl. No. 14/926,982. [cited by applicant]
US Office Actions, mailed on Jun. 7, 2019 and Feb. 13, 2020, in the related U.S. Appl. No. 14/926,844. [cited by applicant]
US Office Actions, mailed on Nov. 6, 2019, Dec. 20, 2019, Jul. 30, 2020 and Nov. 13, 2020, in the related U.S. Appl. No. 16/244,378. [cited by applicant]
The English translation of the Decision to Grant a Patent, mailed on Nov. 8, 2019, in the related Japanese Appl. No. 2016-511014. [cited by applicant]
The English translation of the Brazilian Office Action, mailed on Oct. 7, 2019, in the related Brazilian Appl. No. BR112016014969-6. [cited by applicant]
The extended European Search Report, mailed on May 14, 2021, in the related European Appl. No. 20214926.6. [cited by applicant]
The Canadian Office Action, mailed on Feb. 23, 2021, in the related Canadian Patent Appl. No. 2,932,364. [cited by applicant]
The US Office Action, mailed on May 20, 2021, in the related U.S. Appl. No. 15/947,377. [cited by applicant]
The Notice of Allowance, mailed on May 26, 2021, in the related U.S. Appl. No. 14/926,844. [cited by applicant]
The US Office Action, mailed on Jul. 6, 2021, in the related U.S. Appl. No. 15/947,424. [cited by applicant]
The US Office Action, mailed on Nov. 30, 2021, in the related U.S. Appl. No. 16/422,147. [cited by applicant]
The English translation of the Korean Office Action, mailed on Jul. 30, 2021, in the related Korean Patent Application No. 10-2016-7018968. [cited by applicant]
The US Office Action, mailed on Aug. 4, 2021, in the related U.S. Appl. No. 16/422,147. [cited by applicant]
The Canadian Office Action, mailed on Feb. 2, 2021, in the related Canadian Patent Appl. No. 2,931,986. [cited by applicant]
Yang et al., “Assessment of naturally occurring covalent and total dimer levels in human IgG1 and IgG2” Molecular Immunology 58:108-115 ( 2014). [cited by applicant]
McAuley et al., “Contributions of a disulfide bond to the structure, stability, and dimerization of human IgG1 antibody CH3 domain,” Protein Sci. Jan. 2008; 17(1): 95-106. [cited by applicant]
US Office Action, mailed on Mar. 17, 2021, in the related U.S. Appl. No. 14/926,982. [cited by applicant]
US Office Actions, mailed on Feb. 9, 2021 and Apr. 20, 2021, in the related U.S. Appl. No. 14/926,844. [cited by applicant]
The English translation of the Decision to Grant dated Jul. 26, 2022, in the related Russian Patent Application No. 2020122367/10(038452). [cited by applicant]
The English translation of the Japanese Office Action, mailed on May 16, 2022, in the related Japanese Patent Application No. 2021-092002. [cited by applicant]
The US Office Action, mailed on Aug. 31, 2021, in the related U.S. Appl. No. 15/947,377. [cited by applicant]
The US Office Action, mailed on Feb. 24, 2022, in the related U.S. Appl. No. 15/947,424. [cited by applicant]
Spiekerrnann et al., “Receptor-mediated Immunoglobulin G Transport Across Mucosal Barriers in Adult Life: Functional Expression of FcRn in the Mammalian Lung,” J Exp Med (2002) 196 (3): 303-310. [cited by applicant]
The Canadian Office Action, mailed on Feb. 17, 2022, in the related Canadian Patent Appl. No. 2,904,805. [cited by applicant]
The Chinese Office Action, mailed on Feb. 27, 2023, in the related Chinese Patent Appl. No. 201911344011.0. [cited by applicant]
The English translation of the Japanese Office Action, mailed on Aug. 29, 2023, in the related Japanese Patent Appl. No. 2022-010878. [cited by applicant]
The English translation of the Chinese Office Action, mailed on Aug. 28, 2023, in the related Chinese Patent Appl. No. 202110445639.0. [cited by applicant]
The US Office Action, mailed on Sep. 22, 2023, in the related U.S. Appl. No. 15/947,424. [cited by applicant]
The Third Party Observations, posted on Dec. 1, 2023, in the related European Patent Appl. No. 15700545.5. [cited by applicant]
Hinton et al., “An engineered human IgG1 antibody with longer serum half-life” J Immunol 176(1):346-56 ( 2006). [cited by applicant]
Jansson et al., “All individual domains of staphylococcal protein A show Fab binding,” FEMS Immunology and Medical Microbiology 20 (1998) 69-78. [cited by applicant]
Tustian et al., “Development of purification processes for fully human bispecific antibodies based upon modification of protein A binding avidity,” MAbs May-Jun. 2016;8(4):828-38. [cited by applicant]
The Chinese Office Action, mailed on Jul. 8, 2023, in the related Chinese Patent Appl. No. 201480024044.6. [cited by applicant]
The English translation of the Chinese Office Action, mailed on Nov. 25, 2022, in the related Chinese Patent Appl. No. 201911266804.5. [cited by applicant]
Columbian Office Action, mailed on Jul. 25, 2019, in the related Columbian Patent Application No. 15260305. [cited by applicant]
Taiwanese Search Report, mailed on Jun. 28, 2019, in the related Taiwanese Patent Application No. 103115072. [cited by applicant]
The European Communication, mailed on Oct. 19, 2017, in the related European Appl. No 15700545.5. [cited by applicant]
The US office actions, mailed on Dec. 13, 2017, Mar. 16, 2018 and Sep. 6, 2018, in the related U.S. Appl. No. 14/927,022. [cited by applicant]
The US office action, mailed on Jan. 12, 2023, in the related U.S. Appl. No. 15/947,377. [cited by applicant]
The US office action, mailed on Sep. 23, 2024, in the related U.S. Appl. No. 15/947,424. [cited by applicant]
The US office action, mailed on Oct. 8, 2021, in the related U.S. Appl. No. 16/244,378. [cited by applicant]
The US office action, mailed on Oct. 23, 2024, in the related U.S. Appl. No. 18/079,307. [cited by applicant]
The US office actions, mailed on Aug. 31, 2023 and Mar. 13, 2024, in the related U.S. Appl. No. 17/373,062. [cited by applicant]
The English translation of the Chinese Office Action, mailed on Jul. 8, 2023, in the related Chinese Patent Appl. No. 201480024044.6. [cited by applicant]
The US Office Action, mailed on Aug. 31, 2023, in the related U.S. Appl. No. 17/373,062. [cited by applicant]
DeLano et al., “Convergent Solutions to Binding at a Protein-Protein Interface,” Science, 287:1279-1283, Feb. 18, 2000. [cited by applicant]
The English translation (Google Translate) of the Argentina Office Action, mailed on Dec. 22, 2023, in related Argentina Application No. 20140101718. [cited by applicant]
The English translation of the Chinese Office Action, mailed on Jan. 24, 2024, in the related Chinese Patent Appl. No. 202110445639.0. [cited by applicant]
Cited By (1)
US 12,637,506